2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial by Goldhirsch, Aron, Prof, Gelber, Richard D, Prof, Piccart-Gebhart, Martine J, Prof, de Azambuja, Evandro, MD, Procter, Marion, MSci, Suter, Thomas M, Prof, Jackisch, Christian, Prof, Cameron, David, Prof, Weber, Harald A, MD, Heinzmann, Dominik, PhD, Lago, Lissandra Dal, MD, McFadden, Eleanor, MA, Dowsett, Mitch, Prof, Untch, Michael, Prof, Gianni, Luca, MD, Bell, Richard, Prof, Köhne, Claus-Henning, Prof, Vindevoghel, Anita, MD, Andersson, Michael, MD, Brunt, A Murray, MD, Otero-Reyes, Douglas, MD, Song, Santai, MD, Smith, Ian, Prof, Leyland-Jones, Brian, PhD, Baselga, Jose, Prof

Get full text